BioForce Nanosciences Holdings,
0.8000+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · BFNH · USD
Key Stats
Market Cap
26.82MP/E (TTM)
-Basic EPS (TTM)
-0.04Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
BioForce Nanosciences Holdings posted no revenue for Q2 FY2025 ended June 30, 2025, matching last year, while operating expenses climbed 7.3% year-over-year to $122,781 from higher general and administrative costs. The quarter's net loss of $122,781 edged up from $114,440 in Q2 2024, but year-to-date through six months, net loss ballooned to $1,057,431 versus $245,253 last year, driven by an $801,193 loss on liability settlement from issuing 4,250,000 shares at $0.70 to settle $2,173,000 in accrued director fees. Cash inched up to $905 from $862 at year-end, propped by $43,151 in related-party advances offsetting $43,108 in operating outflows; no debt or capex appears. Shares outstanding rose to 33,521,755, aligning with the $0.03 diluted EPS hit. No non-GAAP metrics disclosed in the 10-Q. Yet cash barely covers basics. Ongoing revenue drought poses the sharpest risk.
10-Q
Q1 FY2025 results
BioForce Nanosciences Holdings posted no revenue for Q1 FY2025 ended March 31, 2025, matching the prior year while operating expenses edged up 2.0% y/y to $133,457 from $130,813, driven by higher general and administrative costs. The net loss ballooned to $934,650 from $130,813 y/y, with the gap stemming from an $801,193 loss on liability settlement after issuing 4,250,000 shares at $0.70 to settle $2,173,000 in accrued director fees. Diluted EPS fell to $(0.03) on 32,246,755 weighted shares, consistent with the net loss and no dilutive securities. Cash climbed to $13,799 from $862 q/q via $28,152 in related-party financing, offsetting $15,215 in operating cash use; free cash flow not disclosed in the 10-Q. Liabilities dropped to $275,041, mainly accrued board compensation, with no debt. Officers funded all expenses through loans. Yet cash won't last long.
10-K
FY2024 results
BioForce Nanosciences Holdings posted zero revenue for FY2024 ended December 31, 2024, matching FY2023's blank slate, with Q4 mirroring the year's revenue drought amid stalled supplement sales. Net loss widened to $490,437 from $471,953, driven by a 37.8% spike in general and administrative expenses to $67,437, largely from professional fees—yet operating cash burn eased slightly to $61,250 annually. No quarterly breakdowns emerge, but the full-year stasis signals stalled momentum in marketing BioForce Eclipse powders. Liquidity clings to $862 in cash against $2.3 million liabilities, propped by chairman advances and $61,474 in financing inflows; no capex or buybacks registered. No guidance disclosed. Supply chain disruptions loom as a key risk, potentially derailing any sales ramp-up.
10-Q
Q3 FY2024 results
BioForce Nanosciences Holdings posted no revenue for Q3 ended September 30, 2024, matching last year, while operating expenses climbed to $122,024 from $113,607, driven by higher professional services (derived). This nudged the net loss up 7.4% year-over-year to $122,024, or $0.00 per diluted share on 29,271,755 shares, aligning with YTD trends where nine-month losses hit $367,277 versus $357,543 prior year. Cash inched to $1,635 from $638 at year-end, propped by $47,412 in financing from related parties and contributions, yet operating cash burn stood at $46,415 with no capex for free cash flow. No debt burdens the balance sheet, but liabilities swelled to $2,180,067 amid accrued director pay. The MOU with Element Global for asset acquisition lingers unresolved. Cash is razor-thin.
10-Q
Q2 FY2024 results
BioForce Nanosciences Holdings posted no revenue for Q2 ended June 30, 2024, matching last year, while operating expenses edged up 0.4% y/y to $114,440 from board compensation and general administrative costs, yielding a net loss of $114,440—flat versus 2023. For the half-year, losses widened slightly 0.6% y/y to $245,253 amid zero sales. Cash trickled to $667, propped by $31,002 in related-party financing that offset $30,973 in operating outflows; no capex means free cash flow mirrors that burn. Stockholders' deficit deepened to $2.1M, with $2.1M liabilities dwarfing assets, yet CEO commitments sustain bare-bones operations. No M&A closed. Controls falter on segregation lapses. Revenue drought persists.
IPO
Employees
Sector
Industry
BDPT
Bioadaptives, Inc.
0.03+0.00
BHST
BioHarvest Sciences Inc.
9.84-0.14
BRBR
BellRing Brands, Inc.
30.84-0.75
CFOO
CHINA FOODS HOLDINGS LTD
0.66+0.00
CYAN
Cyanotech Corp.
0.31+0.00
FTLF
FitLife Brands, Inc.
19.23-0.57
INBP
INTEGRATED BIOPHARMA INC
0.30-0.01
LFVN
Lifevantage Corporation
8.15-0.36
NATR
Nature's Sunshine Products, Inc
13.42-0.43
USNA
USANA Health Sciences, Inc.
19.61-0.72